FDA Requests Additional Information From Makers of Asthma Drugs for Children - DJ
More News related to AZN
- AstraZeneca (AZN) Gets U.S. FDA Approval for SEROQUEL XR Antidepressants
- US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
- Morning Movers 12/03: ICOC, KTCC, FFHL, GNBT, ABK, ISR Higher; PEIX, GRH, OPXA, TRGT, ALOY Lower
- AstraZeneca (AZN) and Targacept (TRGT) To Collaborate to Develop and Commercialize TC-5214 MDD Drug
- Generic Erosion of Established Branded Atypical Antipsychotics Will Cause the Schizophrenia Drug Market To Decline More Than $1 Billion by 2013
More News related to GSK
- Swine Flu Cases Decline to Lowest Level in 2+ Months
- Severe Reactions Spur GlaxoSmithKline to Pull Batch of H1N1 Swine Flu Vaccine in Canada, an Industrial Info News Alert
- Most Surveyed Clinicians Will Prescribe Amgen/GlaxoSmithKline's Prolia as Either a Second- or Third-Line Therapy for Osteoporosis
- Human Genome (HGSI) Raises Money As It Gears Up for Benlysta Approval
- Gilead Sciences (GILD) and Glaxo (GSK) Agree to Commercialize Viread Hep B Treatment in Five Asian Countries
More News related to NVS
- Novartis for Alcon (ACL)? Novartis Says "No" But Market Says "Yes"
- Despite Novartis Denial, UBS Makes A Strong Case That They Should Buy Alcon (ACL)
- Novartis (NVS) has no plans to buy out Alcon (ACL) minority shares - Bloomberg
- Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting
- Vanda Pharma (VNDA) to Receive $200M from Novartis (NVS) Upon Expiration of HSR Antitrust Improvements Act
More News related to FDA
- Unilever (UL) Annouces Total Recall of Slim-Fast Cans
- Steris (STE) Sinks After FDA Notice on Concerns About the Steris System 1 Processor
- Watson Pharmaceuticals (WPI) Files New Drug Application with FDA for Generic Rozerem
- St. Jude (STJ) Receives U.S. FDA Approval for Penta Surgical Lead
- AstraZeneca (AZN) Gets U.S. FDA Approval for SEROQUEL XR Antidepressants
Dow Jones reports the U.S. FDA said it's requested additional information from makers of certain asthma drugs as part of an ongoing safety review of the drugs in children.
The FDA will schedule another advisory panel later this year or early next year to evaluate any new information on the drugs, which include GlaxoSmithKline PLC's (NYSE: GSK) Serevent and Advair, Novartis AG's (NYSE: NVS) and Schering-Plough's (NYSE: SGP) Foradil and AstraZeneca's (NYSE: AZN) Symbicort.
GlaxoSmithKline plc (GSK) is a global healthcare group engaged in the creation, discovery, development, manufacture and marketing of pharmaceutical and consumer health-related products. [SM]
Related Categories
FDAStocks Mentioned
+0.68
-0.23Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
